METFORMIN HYDROCHLORIDE | A212969 | GLENMARK PHARMACEUTICALS LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
BAUSCH HEALTH IRELAND LIMITED et al v. GLENMARK PHARMACEUTICALS LIMITED 4 patentsANDA 212969 | D.N.J. | 2019-05-01 | Terminated 2019-09-05 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.3701
per ea
Lowest NADAC/Unit
$0.2781
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 68462052190METFORMIN ER 1,000 MG GASTR-TB | $0.3701 | EA | Generic | — | 2026-06-17 |
| 68462052001METFORMIN ER 500 MG GASTRC-TB | $0.2781 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.